Display options
Cite
Minhaj FS, Schult RF, Dvorak P, et al. Amphetamine and Clonidine Toxicity Resulting in Posterior Reversible Encephalopathy Syndrome. Pediatr Emerg Care. 2021;37(12):e1721-e1723doi: 10.1097/PEC.0000000000001819.
Minhaj, F. S., Schult, R. F., Dvorak, P., & Nacca, N. (2021). Amphetamine and Clonidine Toxicity Resulting in Posterior Reversible Encephalopathy Syndrome. Pediatric emergency care, 37(12), e1721-e1723. https://doi.org/10.1097/PEC.0000000000001819
Minhaj, Faisal Syed, et al. "Amphetamine and Clonidine Toxicity Resulting in Posterior Reversible Encephalopathy Syndrome." Pediatric emergency care vol. 37,12 (2021): e1721-e1723. doi: https://doi.org/10.1097/PEC.0000000000001819
Minhaj FS, Schult RF, Dvorak P, Nacca N. Amphetamine and Clonidine Toxicity Resulting in Posterior Reversible Encephalopathy Syndrome. Pediatr Emerg Care. 2021 Dec 01;37(12):e1721-e1723. doi: 10.1097/PEC.0000000000001819. PMID: 30973502.
Copy Download .nbib Format: NLM
Share it on

Pediatr Emerg Care. 2021 Dec 01;37(12):e1721-e1723. doi: 10.1097/PEC.0000000000001819.

Amphetamine and Clonidine Toxicity Resulting in Posterior Reversible Encephalopathy Syndrome.

Pediatric emergency care

Faisal Syed Minhaj, Rachel F Schult, Peter Dvorak, Nicholas Nacca

Affiliations

  1. From the Departments of Pharmacy.
  2. Imaging Sciences, University of Rochester Medical Center, Rochester, NY.
  3. Emergency Medicine.

PMID: 30973502 DOI: 10.1097/PEC.0000000000001819

Abstract

ABSTRACT: Amphetamine toxicity typically presents with hypertension and tachycardia. Conversely, clonidine acts as an agonist at central α2 and imidazoline receptors, which may cause brief initial hypertension followed by hypotension and bradycardia in overdose. We report a case of mixed ingestion resulting in posterior reversible encephalopathy syndrome (PRES) successfully treated with phentolamine.A 17-year-old male adolescent presented to the emergency department 2 hours after ingesting up to 25 each of clonidine 0.1-mg tablets and dextroamphetamine 10 mg extended-release capsules. He reported nausea and fatigue with initial blood pressure (BP) 145/95 mm Hg and heart rate (HR) 52 beats per minute (bpm). Nine hours postingestion (HPI), the patient developed headache, photophobia, and confusion with BP 182/111 mm Hg and HR 48 bpm. A computed tomography scan of the head revealed generalized fullness of the cerebellum, upward bulging of the tentorial leaflets, effacement of the fourth ventricle, and crowding of the foramen magnum, suspicious for an atypical presentation of PRES. The patient's systolic BP rose over 200 mm Hg and treated with 2 mg of intravenous phentolamine at 14 HPI. Blood pressure decreased to 133/82 mm Hg, and HR increased to 56 bpm with improvements in headache. Following repeat doses of phentolamine, nicardipine was initiated and increased to 2.5 mg/h for 12 hours. The patient was stable with normal vital signs at 36 HPI.The delayed presentation of hypertensive emergency with PRES may have been due to the actions of extended-release dextroamphetamine and the α2-agonistic effects of clonidine. Phentolamine was chosen for its α1-antagonism and was effective in managing symptoms.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

Conflict of interest statement

Disclosure: The authors declare no conflict of interest.

References

  1. Staykov D, Schwab S. Posterior reversible encephalopathy syndrome. J Intensive Care Med. 2012;27:11–24. - PubMed
  2. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008;29:1036–1042. - PubMed
  3. Masetti R, Cordelli DM, Zama D, et al. PRES in children undergoing hematopoietic stem cell or solid organ transplantation. Pediatrics. 2015;135:890–901. - PubMed
  4. Rowland M. Amphetamine blood and urine levels in man. J Pharm Sci. 1969;58:508–509. - PubMed
  5. Slattum PW, Venitz J, Barr WH. Comparison of methods for the assessment of central nervous system stimulant response after dextroamphetamine administration to healthy male volunteers. J Clin Pharmacol. 1996;36:1039–1050. - PubMed
  6. Wong YN, Wang L, Hartman L, et al. Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers. J Clin Pharmacol. 1998;38:971–978. - PubMed
  7. Davies DS, Wing AM, Reid JL, et al. Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine. Clin Pharmacol Ther. 1977;21:593–601. - PubMed
  8. Fujimura A, Ebihara A, Ohashi KI, et al. Comparison of the pharmacokinetics, pharmacodynamics, and safety of oral (Catapres) and transdermal (M-5041T) clonidine in healthy subjects. J Clin Pharmacol. 1994;34:260–265. - PubMed
  9. Keränen A, Nykänen S, Taskinen J. Pharmacokinetics and side-effects of clonidine. Eur J Clin Pharmacol. 1978;13:97–101. - PubMed
  10. Jang D. Amphetamines. In: Hoffman RSHM, Lewin NA, Nelson LS, eds. Goldfrank's Toxicologic Emergencies. 10th ed. New York, NY: McGraw-Hill; 2017. - PubMed
  11. DeRoos F. Other antihypertensives. In: Hoffman RSHM, Lewin NA, Nelson LS, eds. Goldfrank's Toxicologic Emergencies. 10th ed. New York, NY: McGraw-Hill; 2015. - PubMed
  12. Kobinger W, Walland A. Investigations into the mechanism of the hypotensive effect of 2-(2, 6-dichlorphenylamino)-2-imidazoline-HCl. Eur J Pharmacol. 1967;2:155–162. - PubMed
  13. Fenichel RR. Combining methylphenidate and clonidine: the role of post-marketing surveillance. J Child Adolesc Psychopharmacol. 1995;5:155–156. - PubMed
  14. Phentolamine [package insert]. Eatontown, NJ: West-Ward Pharmaceuticals; 2018. - PubMed
  15. Grossman E, Ironi AN, Messerli FH. Comparative tolerability profile of hypertensive crisis treatments. Drug Saf. 1998;19:99–122. - PubMed

Publication Types